Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo in Richter's Transformation
NCT06936943Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Richter's transformation (RT), sponsored by Ono Pharmaceutical. Primary endpoint: Objective Response Rate at 4 years. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
Richter's transformation (RT)
Beyond the preview
Go deeper on NCT06936943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06936943.